文献速递主动脉疾病

择期主动脉瘤手术中肠系膜下动脉再植入的结局

Outcomes Following Inferior Mesenteric Artery Reimplantation During Elective Aortic Aneurysm Surgery.
PubMed 文献 · Ann Vasc Surg · 2020-01-14

单中心回顾性研究评估2000-2009年择期腹主动脉瘤开放修复术中肠系膜下动脉再植入(IMAR)的结局。840例中70例行IMAR,中位随访98个月,35例有影像随访者中32例(91%)通畅,结肠缺血发生率1.4%,IMAR患者10年生存率30%。

要点

  • IMAR在择期AAA开放手术中用于 select 患者,长期通畅率高达91%。
  • IMAR后结肠缺血发生率为1.4%,仅1例需左半结肠切除。
  • IMAR患者10年生存率30%,肾旁及以上AAA和因术中结肠缺血行IMAR者生存更差。

核心结论

  • 择期AAA开放修复中IMAR对部分患者仍属必要,再植入与优异的长期通畅性和低结肠缺血风险相关。

研究设计与样本

  • 单中心回顾性综述,纳入2000至2009年10年间所有开放主动脉手术中行IMAR的患者,共70例。
  • 同期840例择期腹主动脉瘤重建患者中70例行IMAR,主要结局为通畅性,次要结局为结肠缺血和总生存。

主要发现

  • 70例IMAR患者中35例有随访影像(CT 30例[86%],多普勒5例[14%]),中位随访98个月,32例(91%)确认通畅。
  • 两例通畅丧失均发生在4个月时,无需手术;1例因缺血于术后第9天行左半结肠切除(通畅性未能确认)。
  • IMAR患者结肠缺血发生率为1.4%,中位随访期间总死亡率为51%,10年总生存率为30%。
  • 因术中结肠缺血行IMAR者10年生存率26% vs 34%,肾旁及以上AAA者19.0% vs 38%(P=0.03)。
  • 修复时年龄每增加一岁是生存的唯一统计学显著预测因素(P<0.001),肾旁及以上AAA与死亡风险比1.8(P=0.08)接近显著。

关键数值与推荐

  • IMAR指征包括术中结肠缺血(n=24)、返血差(n=52)、IMA粗大(n=5)、髂内动脉病变(n=5)和既往结肠手术(n=1)。
  • 中位随访98个月时通畅率为91%(32/35),结肠缺血发生率为1.4%。
  • IMAR患者10年总生存率为30%,肾旁及以上AAA者10年生存率19.0% vs 38%(P=0.03)。

临床怎么用

  • 对存在术中结肠缺血、返血差、IMA粗大、髂内动脉病变或既往结肠手术的择期AAA开放修复患者,可考虑行IMAR。
  • IMAR后长期通畅率良好且结肠缺血风险低,但肾旁及以上AAA和因术中结肠缺血行IMAR者生存较差,需加强随访。

局限性

  • 单中心回顾性设计,仅35/70例有随访影像,通畅性数据不完整。
  • 样本量有限,部分比较未达统计学显著性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of inferior mesenteric artery (IMA) reimplantation during open aortic reconstruction is debated. We assessed outcomes after inferior mesenteric artery reimplantation (IMAR) for aortic aneurysmal disease to help shed light on this question. METHODS: A single-center retrospective review of all IMARs performed during open aortic surgery over a 10-year period between 2000 and 2009 was carried out. The primary outcome was patency, while secondary outcomes included colonic ischemia and overall survival. Analysis was performed using Cox models and Kaplan-Meier estimates. RESULTS: Of 840 patients who underwent elective abdominal aortic aneurysm (AAA) reconstructions during this period, 70 underwent IMAR. Indications for IMAR included intraoperative colonic ischemia (n = 24), poor back bleeding (n = 52), large IMA (n = 5), internal iliac disease (n = 5), and prior colon surgery (n = 1). Follow-up imaging studies were available in 35 of 70 patients (computed tomography in 30 [86%] and duplex in 5 [14%]). Patency was confirmed in 32 of 35 patients (91%) over a median follow-up of 98 months. Both losses in patency were at 4 months and did not require an operation. One patient underwent left colon resection on postoperative day 9 because of ischemia. (Patency could not be confirmed.) No statistically significant predictor of patency was noted. Incidence of colonic ischemia was 1.4% in patients undergoing IMAR. The overall mortality was 51% in patients undergoing IMAR over the median follow-up period. The overall 10-year survival was 30% in patients undergoing IMAR for aortic aneurysmal disease. The nature of aneurysm (juxtarenal or higher juxta renal abdominal aortic aneurysm [JRAAA]) was associated with mortality, with a hazard ratio of 1.8 (P = 0.08) approaching significance. Ten-year survival was worse if IMAR was performed for intraoperative colonic ischemia (26% vs 34%) or in JRAAA (19.0% vs 38%; P = 0.03). Age per year at the time of repair was the only statistically significant predictor of survival (P < 0.001). CONCLUSION: IMAR for AAA remains necessary for select patients. Reimplantation is associated with excellent long-term patency and low risk of colonic ischemia.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Jayaraj A, DeMartino RR, Bower TC, et al. Outcomes Following Inferior Mesenteric Artery Reimplantation During Elective Aortic Aneurysm Surgery. Ann Vasc Surg. 2020. PMID: 31953141. doi:10.1016/j.avsg.2019.12.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。